The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030

Journal of Clinical Medicine

Sylvia M. Brakenhoff¹  Milan J. Sonneveld¹  Robert J. de Knegt¹  Bart van Hoek²  Marleen van Dijk³  Joost P. H. Drenth³  Hans Blokzijl⁴  Cas J. Isfordink⁵  Anthonius S. M. Dofferhoff⁶  Cees van Nieuwkoop⁷  Greet Boland⁸  Marc van der Valk⁹  Wei-Han Cheng^1,10 

[1] Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands;Department of Gastroenterology and Hepatology, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands;Department of Gastroenterology and Hepatology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands;Department of Gastroenterology and Hepatology, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands;Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands;Department of Internal Medicine, Canisius Wilhelmina Hospital, Radboud University Medical Centre, 6532 SZ Nijmegen, The Netherlands;Department of Internal Medicine, Haga Teaching Hospital, 2545 AA The Hague, The Netherlands;Department of Medical Microbiology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands;Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands;Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL 60064, USA;

关键词: hepatitis C;    HCV;    elimination;    model;    COVID-19;   

DOI  :  10.3390/jcm10194562

来源: DOAJ

【 摘 要 】

Background: The Netherlands strives for hepatitis C virus (HCV) elimination, in accordance with the World Health Organization targets. An accurate estimate when HCV elimination will be reached is elusive. We have embarked on a nationwide HCV elimination project (CELINE) that allowed us to harvest detailed data on the Dutch HCV epidemic. This study aims to provide a well-supported timeline towards HCV elimination in The Netherlands. Methods: A previously published Markov model was used, adopting published data and unpublished CELINE project data. Two main scenarios were devised. In the Status Quo scenario, 2020 diagnosis and treatment levels remained constant in subsequent years. In the Gradual Decline scenario, an annual decrease of 10% in both diagnoses and treatments was implemented, starting in 2020. WHO incidence target was disregarded, due to low HCV incidence in The Netherlands (≤5 per 100,000). Results: Following the Status Quo and Gradual Decline scenarios, The Netherlands would meet WHO’s elimination targets by 2027 and 2032, respectively. From 2015 to 2030, liver-related mortality would be reduced by 97% in the Status Quo and 93% in the Gradual Decline scenario. Compared to the Status Quo scenario, the Gradual Decline scenario would result in 12 excess cases of decompensated cirrhosis, 18 excess cases of hepatocellular carcinoma, and 20 excess cases of liver-related death from 2020–2030. Conclusions: The Netherlands is on track to reach HCV elimination by 2030. However, it is vital that HCV elimination remains high on the agenda to ensure adequate numbers of patients are being diagnosed and treated.

【 授权许可】

Unknown